Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
IMF Deputy Dan Katz Visits China as Key Economic Review Nears 
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave 
BOJ Governor Ueda Highlights Uncertainty Over Future Interest Rate Hikes 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Dollar Weakens Ahead of Expected Federal Reserve Rate Cut 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
A team of Japanese scientists has developed a method that utilizes glucose and fragmented antibodies in reducing an abnormal accumulation of protein in the brains of mice with Alzheimer’s disease.
According to Takanori Yokota, a neurology professor at the university who was part of the team, they hope accomplishment will lead to the development of a new therapy that is safer and more efficient than its conventional antibody-used counterpart.
The amyloid beta protein accumulation in the brain is believed to trigger Alzheimer’s.
The researchers, primarily from Tokyo Medical and Dental University and the Innovation Center of Nanomedicine (iCONM), encapsulated fragments of an antibody that can attach itself to the protein and remove it from the brain into a so-called nanomachine.
They also attached glucose molecules to the nanomachine's surface, making it simpler for the brain to receive the antibody.
The mice with abnormally high levels of amyloid beta due to the disease were given injections of the encapsulated antibody fragments by the researchers. The agent was administered weekly for 10 weeks.
In contrast to just injecting them there, the study found that employing a nanomachine can deliver 80 times more antibody fragments to the brain.
It was also established that this technique can be used to get rid of amyloid beta lumps, which prevented the protein from gathering.
Because a whole antibody is too large to be placed in many places, the researchers chose to employ antibody fragments instead.
The result was a positive effect that was unanticipated.
Historically, the blood-brain barrier, which determines what to take in from blood vessels to protect the brain, prevented the entire prescribed medication to eliminate the protein from reaching the brain.
Therapeutic antibodies for Alzheimer's disease are well known for having undesirable side effects, such as inflamed brain swelling.
As the fragmented antibody lacks the portion that causes inflammatory reactions, the team anticipates that this side effect may be avoided.
